Loading
Spain's academic haematology trials group, part of the Spanish Society of Haematology. Its working groups cover the leukaemias, myelodysplastic syndromes and, through GEM, myeloma.
PETHEMA, the Programa Español de Tratamientos en Hematología, describes itself as an independent academic cooperative group of haematologists and laboratory researchers from the hospitals of Spain's public health system, some private centres and hospitals in Europe and South America, belonging to the Sociedad Española de Hematología y Hemoterapia (SEHH). The Fundación PETHEMA is its instrument for clinical trials, observational and registry studies. Its working groups include GEM (myeloma), acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, myelodysplastic syndromes and immune thrombocytopenia.
As PETHEMA Foundation it sponsors PEVOLAM (NCT04090736), a phase 3 trial of azacitidine with or without pevonedistat in older or unfit adults with newly diagnosed acute myeloid leukaemia.
Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease.
Led ALCYONE and the smouldering myeloma trials that showed treating early can delay progression to active disease.
Shares Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Shares Acute myeloid leukaemia and the tag cooperative-group.
Shares Acute myeloid leukaemia and the tag cooperative-group.
Shares Multiple myeloma and the tag cooperative-group.
Shares Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Shares Multiple myeloma and the tag cooperative-group.
Shares Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/